In brief
The FDA has initiated a crackdown on telehealth companies like Hims & Hers for promoting unofficial versions of prescription drugs, particularly weight loss medications. In a series of letters, the agency warned these companies that their advertisements are misleading, suggesting that their products are akin to FDA-approved drugs. This action is part of a broader initiative by the Trump administration to ensure truthful pharmaceutical advertisements, following increasing scrutiny over misleading marketing tactics in the healthcare industry.
WASHINGTON (AP) — The FDA is stepping up its scrutiny of telehealth companies that are promoting unofficial versions of prescription medications, including popular weight loss drugs, as part of a crackdown on misleading pharmaceutical advertising initiated by the Trump administration.
In a clear stance against misleading marketing practices, the FDA issued more than 100 letters to online prescribing companies, including notable players like Hims & Hers, which capitalized on the booming demand for less expensive alternatives to well-known obesity treatments.
The letters contain direct warnings to these companies, urging them to cease using misleading promotional claims on their platforms. For example, the agency specifically pointed out Hims & Hers' claim that their customized products contain “the same active ingredient” as FDA-approved drugs such as Wegovy and Ozempic, emphasizing that these formulations, produced by specialty compounding pharmacies, lack FDA scrutiny.
“Your claims imply that your products are the same as an FDA-approved product when they are not,” stated the warning letter dated September 9.
This unprecedented action marks the FDA's first effort to impose advertising regulations on online health platforms that have long asserted they aren't bound by conventional drug marketing rules.
A memo signed by President Donald Trump last week directed Health Secretary Robert F. Kennedy Jr. and the FDA to guarantee that pharmaceutical ads across media platforms are “truthful and non-misleading.” As part of this initiative, the FDA committed to dispatching 100 warning letters to companies over deceptive advertising practices.
The recent FDA letters represent a shift from prior bureaucratic language, adopting a more direct approach with “cease and desist” messaging.
This heightened attention comes as Hims has faced scrutiny due to advertisements, including one aired during the Super Bowl, which touted the benefits of weight-loss medications without disclosing potential side effects or risks. FDA regulations mandate that drug advertisements must provide a balanced presentation of both benefits and risks associated with medical treatments.
Hims, originally known for providing affordable generic options for conditions like hair loss and erectile dysfunction, has diversified to fulfill the increasing demand for obesity medications, offering cheaper versions of these treatments. The FDA has clarified that while compounding of medications is permissible during official shortages, the agency recently determined that such conditions no longer apply to these drugs, suggesting that the practice should cease, except for customized prescriptions.
Industry advocates have raised alarms regarding the impact of pharmaceutical ads on public perception of medication effectiveness and safety, with studies noting that exposure to such advertising can influence patient demands for treatments, even when they are not clinically suitable. The American Medical Association has supported bans on drug advertising, citing its role in inflating demand for expensive new drugs.
As the FDA continues to monitor and respond to misleading health advertisements, the implications of these regulatory efforts underline the significance of transparency in pharmaceutical marketing and patient safety.
